Holen Sie sich die Stockscreener-App
3.38
5.85%
-0.21
Handel nachbörslich:
3.50
0.12
+3.55%
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Defense World
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Light Vision 2024 Shenzhen International Optics Fair - GlobeNewswire Inc.
FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
FDA fast tracks Lipocine's sarcopenia treatment - Investing.com
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire
FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online
Where are the Opportunities in (LPCN) - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - The Eastern Progress Online
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - GuruFocus.com
Lipocine Announces Supply and Distribution Agreement with Pharma - GuruFocus.com
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com
Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com
(LPCN) Trading Signals - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com
Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia
Lipocine reports promising oral brexanolone study results - Investing.com India
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):